[ad_1]
The CEO and co-founder of Germany-based BioNTech, Prof. Dr. Uğur Şahin told US broadcaster CNN the status of the vaccine they carried out with US pharmaceutical giant Pfizer. Prof. Dr. Şahin said they are confident that the vaccine they have developed will be ready for legal approval in mid-October or early November, and then they can begin vaccination. Şahin stated that the vaccine they developed, called ‘BNT162’, is near perfect and they plan to provide 100 million doses by the end of the year and 1.3 billion doses in 2021.
COUNTRIES ALLOW IT SOON
Stating that the vaccine has shown that antibody responses in both young and elderly adults are strong with minimal side effects so far, Prof. Dr. Şahin continued as follows:
“I think we have a safe product and I think this vaccine will be effective. Countries will soon allow these vaccines for emergency use. We don’t see a fever that often. Only a minority of those who participated in the vaccine trials have a fever. We also see much lower symptoms, such as headaches or tiredness. The symptoms seen with these vaccines are temporary, usually seen for a day or two and then disappear.
Tested on 30 thousand people
class = “cf”>
The United States announced in July that it had made a $ 1.95 billion ($ 16.6 billion) deal with Pfizer to produce 100 million doses of the COVID-19 vaccine. The president of the United States, Donald Trump, also emphasized this date when saying that the vaccine against the coronavirus will be ready until the presidential elections of the United States that will take place on November 3. According to the World Health Organization (WHO), the Pfizer and BioNTech vaccine is one of 34 vaccines in clinical trials around the world. Phase 3 trials of 30,000 people, the last stage before the vaccine was launched on the market, began in July.
THE SON OF THE ‘GURBETCI’ FAMILY
Prof. Dr. Uğur Şahin was born on September 19, 1965 in İskenderun. He emigrated to Germany with his family when he was only 4 years old. His family worked at the Ford factory in Cologne. He drew attention to his interest in scientific research and experiments at an early age. Watching the “Immortality is deadly” program prepared on German television about cancer, Uğur Şahin decided to study medicine taking as an example Paul Ehrlich, who discovered the modern immune system in the 19th century and developed cancer chemotherapy for the first time. He studied at the University of Cologne. At the suggestion of his professor, he began working at the Homburg Saar University. He made a name for himself with cancer research. He developed a vaccine that separates the cancer cell from the healthy cell and destroys the cancer cell. It acts on antibodies that defend against diseased cells of breast, colon, lung, pancreas and prostate cancer.
WIFE IS AT THE DIRECTORATE OF THE VACCINES TEAM
His wife, Dr. Was working with Özlem Türeci on a vaccine against skin cancer called melanoma. Dr. Özlem Türeci played an important role in the development of the vaccine as the company’s ‘medical director’. Prof. Şahin headed to this area following the spread of the coronavirus. Şahin founded the BioNTech company in 2008 while working with the Swiss scientist Rolf Zinkernagel, who received the Nobel Prize in Medicine in 1996. At BioNTech, around 80 scientists are currently researching cancer.
class = “cf”>
With the value of July 2020, Prof. The value of the company of which Şahin is a partner is estimated at 3,000 million euros (26,400 million TL). If the vaccine is found, the value of the company is expected to multiply. (SEDAN)
